Patent · US Active

Modified caspase polypeptides and uses thereof

US9434935B2 · kind B2 · utility

17Cited by

38References

9Claims

0Family size

Assignee

Bellicum Pharmaceuticals, Inc. · US

Inventors

David Spencer · Houston, US
Wei-Chun Chang · Fujian, CN

Key dates

Filing date	Mar 10, 2013
Grant date	Sep 6, 2016
Priority date	—
Expiry date	Mar 10, 2033

Classification

Technology area (CPC C)Chemistry; Metallurgy
CPC primaryC12Y502/01008
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

The technology relates in part to compositions comprising modified Caspase-9 polypeptides, compositions comprising nucleic acids coding for modified Caspase-9 polypeptides, chimeric modified Caspase-9 polypeptides, and methods of use thereof, including methods for cell therapy. Methods for cell therapy include modifying transfused cells to express an inducible modified Caspase-9 protein, with reduced basal activity in the absence of the inducer.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.